(Q43115406)

14 November 2017

Renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma (English)

1 reference

14 November 2017

Heinz Ludwig

1

1 reference

14 November 2017

Niklas Zojer

series ordinal

2

1 reference

14 November 2017

language of work or name

English

0 references

publication date

30 March 2010

1 reference

Nature Reviews Clinical Oncology

14 November 2017

1 reference

14 November 2017

7

1 reference

14 November 2017

5

1 reference

14 November 2017

289-294

1 reference

https://scigraph.springernature.com/pub.10.1038/nrclinonc.2010.31

14 November 2017

0 references

cites work

Phase I/II study of ipilimumab for patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.31

21 January 2018

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.31

Cancer incidence and mortality in Europe, 2004

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.31

Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.31

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.31

International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.31

Current multiple myeloma treatment strategies with novel agents: a European perspective

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.31

Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.31

Bortezomib in multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.31

Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.31

PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.31

The potential of proteasome inhibitors in cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.31

Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.31

Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.31

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.31

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.31

Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.31

Pathogenesis and treatment of renal failure in multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.31

Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.31

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.31

Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.31

Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.31

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.31

Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.31

International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.31

Perspectives in multiple myeloma: survival, prognostic factors and disease complications in a single centre between 1975 and 1988.

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20351701

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2010.31

1 reference

Dimensions Publication ID

14 November 2017

0 references

1 reference